EU To Boost Portfolio Of Potential COVID-19 Treatments
A Live Map Of The Most Advanced Candidates Will Be Developed Over Time
The European Commission has set up a new expert group on virus variants whose tasks will include selecting the criteria for identifying possible new treatments and vaccines for COVID-19.
You may also be interested in...
Two products that were on the European Commission’s original list of the “top five” COVID-19 candidate therapeutics in development have been dropped from the latest “top 10” portfolio.
Celltrion continues to eye further markets for its CT-P59 regdanvimab monoclonal antibody treatment for COVID-19, especially in the EU, after winning final approval from the Korean Ministry of Food and Drug Safety.
Coronavirus Notebook: EMA Explains How To Get A Modified Vaccine Approved, UK Starts Oxford/AZ Variant Vaccine Trial
Draft legislation on strengthening the European Medicines Agency’s role in health crises has cleared another hurdle, and the European Commission is inviting companies to a matchmaking event aimed at scaling up the development and production of COVID-19 therapeutics.